TITLE

Potential therapeutic role for statins in respiratory disease

AUTHOR(S)
Hothersall, E.; McSharry, C.; Thomson, N. C.
PUB. DATE
August 2006
SOURCE
Thorax;Aug2006, Vol. 61 Issue 8, p729
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Statins reduce cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and have an established role in the treatment of atherosclerotic disease. Recent research has identified anti-inflammatory properties of statins. Statins appear to reduce the stability of lipid raft formation with subsequent effects on immune activation and regulation, and also prevent the prenylation of signalling molecules with subsequent downregulation of gene expression. Both these effects result in reduced cytokine, chemokine, and adhesion molecule expression, with effects on cell apoptosis or proliferation. This review considers the evidence for the anti-inflammatory properties of statins in the lung, and how these effects are being applied to research into the role of statins as a novel treatment of respiratory diseases.
ACCESSION #
22074188

 

Related Articles

  • Putative Immune Regulatory Role of Statins. Kuipers, Hedwich F.; Van Den Elsen, Peter J. // Current Immunology Reviews;2006, Vol. 2 Issue 1, p55 

    Statins, which are mainly used for treatment of hypercholesterolemia because of their lipid-lowering effects, may also display many immunomodulatory properties. Statins interfere in the mevalonate pathway through inhibition of HMG-CoA reductase activity and thereby affect isoprenylation of...

  • Synergic effect of Eicosapentaenoic acid and Lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells. Notarnicola, Maria; Messa, Caterina; Refolo, Maria G.; Tutino, Valeria; Miccolis, Angelica; Caruso, Maria G. // Lipids in Health & Disease;2010, Vol. 9, p135 

    Background: PUFAs are potent inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an enzyme catalyzing the conversion of HMGCoA to mevalonate, the rate limiting step in cholesterol biosynthesis. Statins represent a class of drugs that are widely used to treat...

  • Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression and activity in spontaneously hypertensive rats. Guo-ping CHEN; Lei YAO; Xian LU; Liang LI; Shen-jiang HU // Acta Pharmacologica Sinica;Oct2008, Vol. 29 Issue 10, p1181 

    Aim: Cardiovascular remodeling is closely associated with cholesterol and is attenuated by statins. The spontaneously hypertensive rat (SHR) has a low serum cholesterol level and evident cardiovascular remodeling. The aims of the present study were to characterize the effects of atorvastatin on...

  • Higher HDL Cholesterol in Statin Therapy, Key to Slowing Atherosclerosis? Eilliott, William T. // Critical Care Alert;Mar20087 Pharmacology Watch, p1 

    The article discusses the effect of higher high density lipoproteins cholesterol in statin therapy on atherosclerosis. A study suggests that people treated with growth hormone are likely to experience soft tissue edema, arthralgias, carpal tunnel syndrome and gynecomastia. They will also...

  • Novel Agents to Manage Dyslipidemias and Impact Atherosclerosis. Nachimuthu, S.; Raggi, P. // Cardiovascular & Haematological Disorders - Drug Targets;Sep2006, Vol. 6 Issue 3, p209 

    Strong epidemiological evidence linked elevated levels of low-density lipoprotein cholesterol (LDL-C) to risk of atherosclerotic heart disease. As a consequence, LDL-C lowering has been the main goal of therapy to reduce cardiovascular risk for the past few decades and...

  • Non-Lipid Effects of Statins: Emerging New Indications. Yildirir, Aylin; M�derrisoglu, Haldun // Current Vascular Pharmacology;Oct2004, Vol. 2 Issue 4, p309 

    Statins are beneficial both in the primary and secondary prevention of atherosclerotic vascular disease and acute events in a broad spectrum of patient subgroups. However, the observed clinical benefit with statin therapy is much greater than expected through the reduction of cholesterol levels...

  • The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels. Keleş, Telat; Bayram, Nihal Akar; Kayhan, Tuğba; Canbay, Alper; Şahin, Deniz; Durmaz, Tahir; Özdemir, Özcan; Aydoğdu, Sinan; Diker, Erdem // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Dec2008, Vol. 8 Issue 6, p407 

    Objective: In this study, we aimed at comparing the effects of standard once daily 20 mg atorvastatin treatment with that of atorvastatin 20 mg administered every other day on serum lipids and high sensitive C-reactive protein (hs-CRP) levels. Methods: Sixty-one patients with serum total...

  • Targeting residual cardiovascular risk: risk high-density lipoprotein cholesterol levels. Hausenloy, D. J.; Yellon, D. M. // Postgraduate Medical Journal;Nov2008, Vol. 84 Issue 997, p590 

    The last 20 years have witnessed dramatic reductions in cardiovascular risk using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") to lower levels of low-density lipoprotein cholesterol (LDL-C). Using this approach one can achieve a reduction in the risk of major...

  • Why The Lipid Hypothesis Is Wrong.  // Health & Stress;Dec2012, Vol. 24 Issue 12, p7 

    The article outlines the author's presentation about statins as the solution for inflammation caused by coronary heart disease. The said presentation aims at explaining that inflammation was more likely to be the result of atherosclerosis plaque and the coronary atherosclerosis was not due to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics